Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.

Journal of neurology - 1 Mar 2009

Hassin-Baer Sharon, Laitman Yael, Azizi Esther, Molchadski Irena, Galore-Haskel Gilli, Barak Frida, Cohen Oren S, Friedman Eitan

Abstract excerpt

BACKGROUND: A single missense mutation (G2019S) in the leucine rich repeat kinase 2 (LRRK2) gene has been reported to be prevalent among Ashkenazi Jewish patients with Parkinson disease (PD). An association between malignant melanoma (MM) and PD was also recently reported. The nature of this association is still elusive. OBJECTIVE: To evaluate the rate of the G2019S(*) LRKK2 mutation among ethnically diverse,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Ethnicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Israel

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Melanoma

Share to Parkinson Disease

Share to Protein Serine-Threonine Kinases

Source

Identifiers

PMID: 19412725
DOI: 10.1007/s00415-009-0117-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.PMID 19412725Read ↗

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?Semantic proximity Read ↗

The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.Semantic proximity Read ↗

The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.Semantic proximity Read ↗

The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.Semantic proximity Read ↗

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.Semantic proximity Read ↗

LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s DiseaseSemantic proximity Read ↗

Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects.Semantic proximity Read ↗

Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.Semantic proximity Read ↗

Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.Semantic proximity Read ↗

Parkinson's disease associated with LRRK2-R1441C mutation: Characterization and comparison with other LRRK2 mutations.Semantic proximity Read ↗

The age at onset of LRRK2 p.Gly2019Ser Parkinson’s disease across ancestries and countries of originSemantic proximity Read ↗

LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.